OFS
REGN icon

OneAscent Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

OneAscent Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-436
Closed -$313K – 288
2023
Q2 		$313K Sell
436
-66
-13% -$50.9K 0.14% 81
2023
Q1 		$412K Buy
502
+76
+18% +$57.3K 0.17% 75
2022
Q4 		$307K Buy
+426
New +$314K 0.13% 109
2022
Q1 		– Sell
-530
Closed -$335K – 178
2021
Q4 		$335K Buy
+530
New +$326K 0.64% 63

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OneAscent Financial Services's REGN Position: Q3 2023 in Review

OneAscent Financial Services sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 436 shares — an estimated $313K sold.

OneAscent Financial Services first reported a position in REGN in Q4 2021 and held it in 4 quarters. The position peaked at $412K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • OneAscent Financial Services reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • OneAscent Financial Services sold 436 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $313K.
  • OneAscent Financial Services first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • OneAscent Financial Services's Regeneron Pharmaceuticals position peaked at $412K in Q1 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on OneAscent Financial Services's 13F filing for Q3 2023, filed 13 Oct 2023.